Colloidal bismuth pectin‐containing quadruple therapy as the first‐line treatment of Helicobacter pylori infection: A multicenter, randomized, double‐blind, non‐inferiority clinical trial

Abstract

AbstractBackgroundBismuth‐containing quadruple therapy is an effective regimen for Helicobacter pylori (H. pylori) treatment. No head‐to‐head comparison trials have been conducted to evaluate the efficacy of colloidal bismuth pectin (CBP) in quadruple therapy for eradicating H. pylori. We aimed to compare the efficacy and safety of CBP quadruple therapy and bismuth potassium citrate (BPC) quadruple therapy for 14 days in the first‐line treatment of H. pylori.MethodsIn this multicenter, randomized, double‐blind, non‐inferiority clinical trial, H. pylori‐infected subjects without eradication history were randomized to receive amoxicillin 1 g twice daily, tetracycline 500 mg three time daily, esomeprazole 20 mg twice daily in combination with CBP 200 mg three time daily or BPC 240 mg twice daily for 14 days. 13C‐urea breath tests were used to access the eradication rate at least 4 weeks after treatment.ResultsBetween April 2021 and July 2022, 406 patients were assessed for eligibility and 339 subjects were randomized. The cure rates (primary outcome) of CBP and BPC quadruple therapy were 90.5% and 92.3% (p = 0.56) by intention‐to‐treat analysis, respectively, and 96.1% and 96.2% (p = 1.00) by per‐protocol analysis, respectively. CBP quadruple therapy was non‐inferior to BPC quadruple therapy in the intention‐to‐treat and per‐protocol analysis (p < 0.025). The frequency of adverse events and compliance were not different among the two groups (p > 0.05).ConclusionsBoth CBP and BPC quadruple therapy for 14 days provide high efficacy, good compliance, and safety in the first‐line treatment of H. pylori in China.